Skip to main content
Erschienen in: Tumor Biology 4/2013

01.08.2013 | Research Article

XRCC1 Arg194Trp polymorphism is associated with oral cancer risk: evidence from a meta-analysis

verfasst von: Yi Zhang, Yin Wang, Jian Wu, Long-Jiang Li

Erschienen in: Tumor Biology | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Previous studies show that X-ray cross-complementing group 1 (XRCC1) Arg194Trp may result in variations in host’s repair efficiency of DNA damage, and this repair deficit may eventually cause individual susceptibility to oral cancer. However, published data regarding the association between XRCC1 Arg194Trp polymorphism and oral cancer risk were contradictory. The aim of this study was to derive a more precise estimation of the association of XRCC1 Arg194Trp polymorphism with oral cancer by performing a meta-analysis. Odds ratios (ORs) and 95 % confidence intervals (95 % CIs) were used to assess the strength of the association. Finally, a meta-analysis of nine eligible studies including 1,281 cases and 1,966 controls was performed. Overall, there was a significant association between XRCC1 Arg194Trp polymorphism and oral cancer risk (for Trp versus Arg: OR = 1.41, 95 % CI 1.08–1.83, P = 0.01; for TrpTrp versus ArgArg: OR = 1.50, 95 % CI 1.00–2.30, P = 0.05; for TrpTrp/ArgTrp versus ArgArg: OR = 1.49, 95 % CI 1.14–1.94, P = 0.003). After excluding those studies containing patients with oral leukoplakia, there was still an obvious association between XRCC1 Arg194Trp polymorphism and oral cancer risk (for TrpTrp/ArgTrp versus ArgArg: OR = 1.40, 95 % CI 1.14–1.71, P = 0.001). Subgroup analysis by ethnicity suggested that there was an obvious association between XRCC1 Arg194Trp polymorphism and oral cancer risk in Asians under three genetic models. In conclusion, the results from this meta-analysis suggest that XRCC1 Arg194Trp polymorphism is associated with oral cancer risk, especially in Asians.
Literatur
1.
Zurück zum Zitat Curtin NJ. DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer. 2012;12:801–17.PubMedCrossRef Curtin NJ. DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer. 2012;12:801–17.PubMedCrossRef
2.
Zurück zum Zitat Jin B, Robertson KD. DNA methyltransferases, DNA damage repair, and cancer. Adv Exp Med Biol. 2013;754:3–29.PubMedCrossRef Jin B, Robertson KD. DNA methyltransferases, DNA damage repair, and cancer. Adv Exp Med Biol. 2013;754:3–29.PubMedCrossRef
3.
Zurück zum Zitat Karahalil B, Bohr VA, Wilson 3rd DM. Impact of DNA polymorphisms in key DNA base excision repair proteins on cancer risk. Hum Exp Toxicol. 2012;31:981–1005.PubMedCrossRef Karahalil B, Bohr VA, Wilson 3rd DM. Impact of DNA polymorphisms in key DNA base excision repair proteins on cancer risk. Hum Exp Toxicol. 2012;31:981–1005.PubMedCrossRef
4.
Zurück zum Zitat Kazak L, Reyes A, Holt IJ. Minimizing the damage: repair pathways keep mitochondrial DNA intact. Nat Rev Mol Cell Biol. 2012;13:659–71.PubMedCrossRef Kazak L, Reyes A, Holt IJ. Minimizing the damage: repair pathways keep mitochondrial DNA intact. Nat Rev Mol Cell Biol. 2012;13:659–71.PubMedCrossRef
5.
Zurück zum Zitat Maugeri-Sacca M, Bartucci M, De Maria R. DNA damage repair pathways in cancer stem cells. Mol Cancer Ther. 2012;11:1627–36.PubMedCrossRef Maugeri-Sacca M, Bartucci M, De Maria R. DNA damage repair pathways in cancer stem cells. Mol Cancer Ther. 2012;11:1627–36.PubMedCrossRef
6.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
7.
Zurück zum Zitat Saman DM. A review of the epidemiology of oral and pharyngeal carcinoma: update. Head Neck Oncol. 2012;4:1.PubMedCrossRef Saman DM. A review of the epidemiology of oral and pharyngeal carcinoma: update. Head Neck Oncol. 2012;4:1.PubMedCrossRef
8.
Zurück zum Zitat Lubek JE, Clayman L. An update on squamous carcinoma of the oral cavity, oropharynx, and maxillary sinus. Oral Maxillofac Surg Clin North Am. 2012;24:307–16. x.PubMedCrossRef Lubek JE, Clayman L. An update on squamous carcinoma of the oral cavity, oropharynx, and maxillary sinus. Oral Maxillofac Surg Clin North Am. 2012;24:307–16. x.PubMedCrossRef
9.
Zurück zum Zitat Yen CY, Liu SY, Chen CH, Tseng HF, Chuang LY, Yang CH, et al. Combinational polymorphisms of four DNA repair genes XRCC1, XRCC2, XRCC3, and XRCC4 and their association with oral cancer in Taiwan. J Oral Pathol Med. 2008;37:271–7.PubMedCrossRef Yen CY, Liu SY, Chen CH, Tseng HF, Chuang LY, Yang CH, et al. Combinational polymorphisms of four DNA repair genes XRCC1, XRCC2, XRCC3, and XRCC4 and their association with oral cancer in Taiwan. J Oral Pathol Med. 2008;37:271–7.PubMedCrossRef
10.
Zurück zum Zitat Ramachandran S, Ramadas K, Hariharan R, Rejnish Kumar R, Radhakrishna Pillai M. Single nucleotide polymorphisms of DNA repair genes XRCC1 and XPD and its molecular mapping in Indian oral cancer. Oral Oncol. 2006;42:350–62.PubMedCrossRef Ramachandran S, Ramadas K, Hariharan R, Rejnish Kumar R, Radhakrishna Pillai M. Single nucleotide polymorphisms of DNA repair genes XRCC1 and XPD and its molecular mapping in Indian oral cancer. Oral Oncol. 2006;42:350–62.PubMedCrossRef
11.
Zurück zum Zitat Mahimkar MB, Samant TA, Kannan S, Patil T. Influence of genetic polymorphisms on frequency of micronucleated buccal epithelial cells in leukoplakia patients. Oral Oncol. 2010;46:761–6.PubMedCrossRef Mahimkar MB, Samant TA, Kannan S, Patil T. Influence of genetic polymorphisms on frequency of micronucleated buccal epithelial cells in leukoplakia patients. Oral Oncol. 2010;46:761–6.PubMedCrossRef
12.
Zurück zum Zitat Dos Reis MB, Losi-Guembarovski R, de Souza Fonseca Ribeiro EM, Cavalli IJ, Morita MC, Ramos GH, et al. Allelic variants of XRCC1 and XRCC3 repair genes and susceptibility of oral cancer in Brazilian patients. J Oral Pathol Med. 2013;42:180–5.PubMedCrossRef Dos Reis MB, Losi-Guembarovski R, de Souza Fonseca Ribeiro EM, Cavalli IJ, Morita MC, Ramos GH, et al. Allelic variants of XRCC1 and XRCC3 repair genes and susceptibility of oral cancer in Brazilian patients. J Oral Pathol Med. 2013;42:180–5.PubMedCrossRef
13.
Zurück zum Zitat Kietthubthew S, Sriplung H, Au WW, Ishida T. Polymorphism in DNA repair genes and oral squamous cell carcinoma in Thailand. Int J Hyg Environ Health. 2006;209:21–9.PubMedCrossRef Kietthubthew S, Sriplung H, Au WW, Ishida T. Polymorphism in DNA repair genes and oral squamous cell carcinoma in Thailand. Int J Hyg Environ Health. 2006;209:21–9.PubMedCrossRef
14.
Zurück zum Zitat Hung RJ, Hall J, Brennan P, Boffetta P. Genetic polymorphisms in the base excision repair pathway and cancer risk: a huge review. Am J Epidemiol. 2005;162:925–42.PubMedCrossRef Hung RJ, Hall J, Brennan P, Boffetta P. Genetic polymorphisms in the base excision repair pathway and cancer risk: a huge review. Am J Epidemiol. 2005;162:925–42.PubMedCrossRef
15.
Zurück zum Zitat Hu Z, Ma H, Chen F, Wei Q, Shen H. XRCC1 polymorphisms and cancer risk: a meta-analysis of 38 case–control studies. Cancer Epidemiol Biomark Prev. 2005;14:1810–8.CrossRef Hu Z, Ma H, Chen F, Wei Q, Shen H. XRCC1 polymorphisms and cancer risk: a meta-analysis of 38 case–control studies. Cancer Epidemiol Biomark Prev. 2005;14:1810–8.CrossRef
16.
Zurück zum Zitat Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–29.CrossRef Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–29.CrossRef
17.
Zurück zum Zitat Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
18.
Zurück zum Zitat DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRef DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRef
19.
Zurück zum Zitat Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRef Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRef
20.
Zurück zum Zitat Majumder M, Sikdar N, Ghosh S, Roy B. Polymorphisms at XPD and XRCC1 DNA repair loci and increased risk of oral leukoplakia and cancer among NAT2 slow acetylators. Int J Cancer. 2007;120:2148–56.PubMedCrossRef Majumder M, Sikdar N, Ghosh S, Roy B. Polymorphisms at XPD and XRCC1 DNA repair loci and increased risk of oral leukoplakia and cancer among NAT2 slow acetylators. Int J Cancer. 2007;120:2148–56.PubMedCrossRef
21.
Zurück zum Zitat Ho T, Li G, Lu J, Zhao C, Wei Q, Sturgis EM. X-ray repair cross-complementing group 1 (XRCC1) single-nucleotide polymorphisms and the risk of salivary gland carcinomas. Cancer. 2007;110:318–25.PubMedCrossRef Ho T, Li G, Lu J, Zhao C, Wei Q, Sturgis EM. X-ray repair cross-complementing group 1 (XRCC1) single-nucleotide polymorphisms and the risk of salivary gland carcinomas. Cancer. 2007;110:318–25.PubMedCrossRef
22.
Zurück zum Zitat Hillbertz NS, Hirsch JM, Jalouli J, Jalouli MM, Sand L. Viral and molecular aspects of oral cancer. Anticancer Res. 2012;32:4201–12.PubMed Hillbertz NS, Hirsch JM, Jalouli J, Jalouli MM, Sand L. Viral and molecular aspects of oral cancer. Anticancer Res. 2012;32:4201–12.PubMed
23.
Zurück zum Zitat Mishra R. Biomarkers of oral premalignant epithelial lesions for clinical application. Oral Oncol. 2012;48:578–84.PubMedCrossRef Mishra R. Biomarkers of oral premalignant epithelial lesions for clinical application. Oral Oncol. 2012;48:578–84.PubMedCrossRef
24.
Zurück zum Zitat Sperka T, Wang J, Rudolph KL. DNA damage checkpoints in stem cells, ageing and cancer. Nat Rev Mol Cell Biol. 2012;13:579–90.PubMedCrossRef Sperka T, Wang J, Rudolph KL. DNA damage checkpoints in stem cells, ageing and cancer. Nat Rev Mol Cell Biol. 2012;13:579–90.PubMedCrossRef
25.
Zurück zum Zitat Papamichos-Chronakis M, Peterson CL. Chromatin and the genome integrity network. Nat Rev Genet. 2013;14:62–75.PubMedCrossRef Papamichos-Chronakis M, Peterson CL. Chromatin and the genome integrity network. Nat Rev Genet. 2013;14:62–75.PubMedCrossRef
26.
Zurück zum Zitat Ginsberg G, Angle K, Guyton K, Sonawane B. Polymorphism in the DNA repair enzyme XRCC1: utility of current database and implications for human health risk assessment. Mutat Res. 2011;727:1–15.PubMedCrossRef Ginsberg G, Angle K, Guyton K, Sonawane B. Polymorphism in the DNA repair enzyme XRCC1: utility of current database and implications for human health risk assessment. Mutat Res. 2011;727:1–15.PubMedCrossRef
27.
Zurück zum Zitat Huang J, Zhang J, Zhao Y, Liao B, Liu J, Li L, et al. The Arg194Trp polymorphism in the XRCC1 gene and cancer risk in Chinese Mainland population: a meta-analysis. Mol Biol Rep. 2011;38:4565–73.PubMedCrossRef Huang J, Zhang J, Zhao Y, Liao B, Liu J, Li L, et al. The Arg194Trp polymorphism in the XRCC1 gene and cancer risk in Chinese Mainland population: a meta-analysis. Mol Biol Rep. 2011;38:4565–73.PubMedCrossRef
28.
Zurück zum Zitat Li Y, Liu F, Tan SQ, Wang Y, Li SW. X-ray repair cross-complementing group 1 (XRCC1) genetic polymorphisms and cervical cancer risk: a huge systematic review and meta-analysis. PLoS One. 2012;7:e44441.PubMedCrossRef Li Y, Liu F, Tan SQ, Wang Y, Li SW. X-ray repair cross-complementing group 1 (XRCC1) genetic polymorphisms and cervical cancer risk: a huge systematic review and meta-analysis. PLoS One. 2012;7:e44441.PubMedCrossRef
29.
Zurück zum Zitat Zhang H, Li W, Franklin MJ, Dudek AZ. Polymorphisms in DNA repair gene XRCC1 and skin cancer risk: a meta-analysis. Anticancer Res. 2011;31:3945–52.PubMed Zhang H, Li W, Franklin MJ, Dudek AZ. Polymorphisms in DNA repair gene XRCC1 and skin cancer risk: a meta-analysis. Anticancer Res. 2011;31:3945–52.PubMed
30.
Zurück zum Zitat Chen B, Zhou Y, Yang P, Wu XT. Polymorphisms of XRCC1 and gastric cancer susceptibility: a meta-analysis. Mol Biol Rep. 2012;39:1305–13.PubMedCrossRef Chen B, Zhou Y, Yang P, Wu XT. Polymorphisms of XRCC1 and gastric cancer susceptibility: a meta-analysis. Mol Biol Rep. 2012;39:1305–13.PubMedCrossRef
31.
Zurück zum Zitat Li J, Li Z, Feng L, Guo W, Zhang S. Polymorphisms of DNA repair gene XRCC1 and hepatocellular carcinoma risk among East Asians: a meta-analysis. Tumour Biol. 2013;34:261–9.PubMedCrossRef Li J, Li Z, Feng L, Guo W, Zhang S. Polymorphisms of DNA repair gene XRCC1 and hepatocellular carcinoma risk among East Asians: a meta-analysis. Tumour Biol. 2013;34:261–9.PubMedCrossRef
32.
Zurück zum Zitat Zeng FR, Ling Y, Yang J, Tian XC, Yang X, Luo RC. X-ray repair cross-complementing group 1 Arg399Gln gene polymorphism and susceptibility to colorectal cancer: a meta-analysis. Tumour Biol. 2013;34:555–63.PubMedCrossRef Zeng FR, Ling Y, Yang J, Tian XC, Yang X, Luo RC. X-ray repair cross-complementing group 1 Arg399Gln gene polymorphism and susceptibility to colorectal cancer: a meta-analysis. Tumour Biol. 2013;34:555–63.PubMedCrossRef
Metadaten
Titel
XRCC1 Arg194Trp polymorphism is associated with oral cancer risk: evidence from a meta-analysis
verfasst von
Yi Zhang
Yin Wang
Jian Wu
Long-Jiang Li
Publikationsdatum
01.08.2013
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2013
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0779-y

Weitere Artikel der Ausgabe 4/2013

Tumor Biology 4/2013 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.